Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 441.05 -2.05 (-0.46%) Market Cap: 112.08 Bil Enterprise Value: 107.49 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 73/100

Vertex Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 06:30PM GMT
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Hi, everyone. My name is Evan Seigerman. I'm the senior large-cap biotechnology analyst here at Crédit Suisse. And it's my distinct pleasure to have Vertex Pharmaceuticals. And from Vertex, I have Reshma Kewalramani, that was a tough one, the current CMO, incoming CEO next year. And of course, Charlie Wagner, CFO; and also Michael Partridge from the IR team.

So thank you very much for coming to Scottsdale. My pleasure to have both of you here. And before we jump into Q&A, can you just give some high-level comments as to where Vertex is, highlighting the recent amazing progress?

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - Chief Medical Officer

Absolutely. Well, first of all, Evan, thanks for the invitation. Charlie and I are delighted to be here. For those of you joining on webcast, welcome to all of you as well. Maybe, Evan, let me just do some formalities and give you our safe harbor statement. We are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot